115372 Results

People

  1. Ladanyi
    Ladanyi
  2. Motzer
    Motzer
  3. Reuter
    Reuter
  4. Scher
    Scher
  5. Brennan
    Brennan
  6. Giralt
    Giralt
  7. Gonen
    Gonen
  8. Perales
    Perales
  9. Hudis
    Hudis
  10. Jarnagin
    Jarnagin

Groups

  1. Department of Medicine (39034)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22057)
  4. Surgery (21249)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15763)
  7. Center for Hematologic Malignancies (13263)
  8. Hematologic Malignancies, Division of (13087)
  9. Sloan Kettering Institute Postdocs (12936)
  10. Department of Pathology and Laboratory Medicine (12615)
Formats
  1. Journal Article (66748)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3743)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (661)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39034)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22057)
  4. Surgery (21249)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15763)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1050)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5599)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115372)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase II trial of tepotinib in patients with non-small cell lung cancer (NSCLC) harboring MET alterations: The VISION study
    Meeting Abstract

    Paik, P.; Cortot, A.; Felip, E.; Sakai, H.; Mazieres, J.; Horn, L.; Griesinger, F.; Bruns, R.; Scheele, J.; Straub, J.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • ANCHOR CRC: A phase 2, open-label, single arm, multicenter study of encorafenib (ENCO), binimetinib (BIM), plus cetuximab (CETUX) in patients with previously untreated BRAF V600E-mutant metastatic colorectal cancer (mCRC)
    Meeting Abstract

    Grothey, A.; Yaeger, R.; Paez, D.; Tabernero, J.; Taïeb, J.; Yoshino, T.; Groc, M.; Vedovato, J.; Chetaille, E.; Van Cutsem, E.
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Impact of prognostic factors and risk groups on overall survival in patients treated with pembrolizumab vs investigator’s choice chemotherapy for advanced urothelial cancer: Post HOC analysis of Keynote-045
    Meeting Abstract

    Gurney, H.; Bellmunt, J.; de Wit, R.; Vaughn, D. J.; Fradet, Y.; Lee, J. L.; Fong, L.; Vogelzang, N. J.; Climent, M. A.; Petrylak, D. P.; more...
    Asia-Pacific Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Outcomes based on Albumin-Bilirubin (ALBI) grade in the phase 3 CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellulat carcinoma (HCC)
    Meeting Abstract

    Miksad, R.; Cicin, I.; Chen, Y.; Klumpen, H.; Kim, S.; Lin, Z.; Youkstetter, J.; Sen, S.; Cheng, A.; Meyer, T.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Phase 3 multicenter, open-label, randomized study of infigratinib versus gemcitabine plus cisplatin in the first-line treatment of patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial
    Meeting Abstract

    Javle, M.; Borbath, I.; Clarke, S.; Hitre, E.; Louvet, C.; Macarulla, T.; Oh, D.; Spratlin, J.; Valle, J.; Weiss, K.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Update on the phase II SUMMIT trial: Neratinib + fulvestrant for HER2-mutant, HR-positive, metastatic breast cancer
    Meeting Abstract

    Smyth, L. M.; Saura, C.; Piha-Paul, S. A.; Lu, J.; Mayer, I. A.; Brufksy, A. M.; Spanggaard, I.; Arnedos, M.; Cutler, R. E.; Hyman, D. M.
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • A phase II study of [fam-] trastuzumab deruxtecan (DS-8201a) in HER2-overexpressing or -mutated advanced non-small cell lung cancer
    Meeting Abstract

    Planchard, D.; Li, B. T.; Murakami, H.; Shiga, R.; Lee, C. C.; Wang, K.; Jänne, P. A.
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Crizotinib in advanced ROS1-rearranged non-small cell lung cancer (NSCLC): Overall survival (OS) and updated safety from PROFILE 1001
    Meeting Abstract

    Shaw, A.; Riely, G. J.; Bang, Y. J.; Kim, D. W.; Camidge, D. R.; Shapiro, G. I.; Usari, T.; Wang, S. C.; Wilner, K.; Clark, J. W.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • VOYAGER: An open-label, randomised, phase 3 study of avapritinib vs regorafenib in patients with locally advanced metastatic or unresectable gastrointestinal stromal tumour
    Meeting Abstract

    Bauer, S.; George, S.; Kang, Y.; Jones, R.; Mir, O.; Tap, W.; Doyle, A.; Picazio, N.; Zhou, T.; Roche, M.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Double PIK3CA mutations in cis enhance PI3Kα oncogene activation and sensitivity to PI3Kα inhibitors in breast cancer
    Meeting Abstract

    Vasan, N.; Razavi, P.; Johnson, J. L.; Shao, H.; Reznik, E.; Smith, M. L.; Sebra, R.; Cantley, L. C.; Scaltriti, M.; Baselga, J.
    Annals of Oncology (2019)

    Fulltext@MSK | Save